On August 14, 2025, BioLineRx Ltd. reported its unaudited financial results for the second quarter ended June 30, 2025, and provided an updated cash runway guidance. The company now projects its capital to fund operations into the first half of 2027, an extension from previous guidance, explicitly incorporating projected development costs for new assets.
Total revenues for Q2 2025 were $0.304 million, consisting entirely of royalties from Ayrmid's commercialization of APHEXDA, compared to $5.393 million in Q2 2024. The net loss for the quarter was $3.940 million, reflecting the shift from direct sales to a royalty-based model.
Operating expenses remained significantly reduced, with sales and marketing expenses at zero, down from $6.415 million in Q2 2024. BioLineRx reported approximately $28.2 million in cash and equivalents as of June 30, 2025, and confirmed continued progress in evaluating potential pipeline expansion opportunities, targeting a transaction in 2025.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.